Dai, Kun <br/><br/>
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.  [electronic resource] 

 -  Oncotarget  Jan 2016 
 - 4770-84 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.6613  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Bone Morphogenetic Protein Receptors, Type I--metabolism<br/>Breast Neoplasms--drug therapy<br/>Bridged-Ring Compounds--administration & dosage<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoenzyme Techniques<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Grading<br/>Neoplasm Invasiveness<br/>Neoplasm Staging<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Retrospective Studies<br/>Survival Rate<br/>Taxoids--administration & dosage